These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8428370)

  • 1. National Cancer Institute workshop on the possible roles of metallothionein in carcinogenesis.
    Cherian MG; Huang PC; Klaassen CD; Liu YP; Longfellow DG; Waalkes MP
    Cancer Res; 1993 Feb; 53(4):922-5. PubMed ID: 8428370
    [No Abstract]   [Full Text] [Related]  

  • 2. [Metallothionein and cancer].
    Li X; Ru B
    Wei Sheng Yan Jiu; 1999 May; 28(3):185-7. PubMed ID: 12712730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metallothionein in carcinogenesis and cancer chemotherapy.
    Ebadi M; Iversen PL
    Gen Pharmacol; 1994 Nov; 25(7):1297-310. PubMed ID: 7896039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Report of the Cancer Chemotherapy Collaborative Program Review Committee: the Richardson report. June 1966, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
    Cancer Treat Rep; 1984 Jan; 68(1):343-56. PubMed ID: 6692435
    [No Abstract]   [Full Text] [Related]  

  • 5. As memory serves--an informal history of the National Cancer Institute, 1937-57.
    Shimkin MB
    J Natl Cancer Inst; 1977 Aug; 59(2 Suppl):559-600. PubMed ID: 328903
    [No Abstract]   [Full Text] [Related]  

  • 6. The role of metallothioneins in anticancer drug resistance.
    Bahnson RR; Basu A; Lazo JS
    Cancer Treat Res; 1991; 57():251-60. PubMed ID: 1686720
    [No Abstract]   [Full Text] [Related]  

  • 7. Origins and development of chemotherapy research at the National Cancer Institute.
    Zubrod CG
    Cancer Treat Rep; 1984 Jan; 68(1):9-19. PubMed ID: 6362871
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical development of anticancer agents--a National Cancer Institute perspective.
    Marsoni S; Wittes R
    Cancer Treat Rep; 1984 Jan; 68(1):77-85. PubMed ID: 6362870
    [No Abstract]   [Full Text] [Related]  

  • 9. Alternation of chemotherapy and radiotherapy in cancer management. I. Summary of the Division of Cancer Treatment Workshop.
    Looney WB; Goldie JH; Little JB; Hopkins HA; Read EJ; Wittes R
    Cancer Treat Rep; 1985; 69(7-8):769-75. PubMed ID: 4016787
    [No Abstract]   [Full Text] [Related]  

  • 10. The evaluation of cytotoxic drugs.
    Von Hoff DD; Rozencweig M; Muggia FM
    Cancer Treat Rev; 1979 Jun; 6 Suppl():1-8. PubMed ID: 498161
    [No Abstract]   [Full Text] [Related]  

  • 11. [Role of metallothionein in cancer chemotherapy].
    Naganuma A; Imura N
    Gan To Kagaku Ryoho; 1994 Feb; 21(3):301-6. PubMed ID: 8109985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The national program for cancer chemotherapy.
    Zubrod CG
    JAMA; 1972 Nov; 222(9):1161-2. PubMed ID: 4678048
    [No Abstract]   [Full Text] [Related]  

  • 13. The role of the National Cancer Institute in drug development.
    Doroshow J
    Clin Adv Hematol Oncol; 2005 Apr; 3(4):257-8. PubMed ID: 16166997
    [No Abstract]   [Full Text] [Related]  

  • 14. 3. Proposal for the National Cancer Institute Cancer Chemotherapy Program.
    Cancer Chemother Rep; 1966 Oct; 50(7):461-540. PubMed ID: 5919868
    [No Abstract]   [Full Text] [Related]  

  • 15. C.R.O.S. conference on combined modalities chemotherapy/radiotherapy. Hilton Head Island, South Carolina, November 15--18, 1978.
    Carter SK
    Cancer Chemother Pharmacol; 1979; 2(2):139-42. PubMed ID: 43777
    [No Abstract]   [Full Text] [Related]  

  • 16. Reports from the Workshop on the Use of Steroids as Carriers of Cytotoxic Agents in Breast Cancer: Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute.
    Cancer Treat Rep; 1978 Aug; 62(8):1239. PubMed ID: 28830
    [No Abstract]   [Full Text] [Related]  

  • 17. Cancer research program strategy and planning--the use of contracts for program implementation.
    Baker CG
    J Natl Cancer Inst; 1977 Aug; 59(2 Suppl):651-69. PubMed ID: 328910
    [No Abstract]   [Full Text] [Related]  

  • 18. The cooperative clinical research program of the National Cancer Institute.
    Foye LV
    Am J Roentgenol Radium Ther Nucl Med; 1970 Jan; 108(1):14-8. PubMed ID: 5410698
    [No Abstract]   [Full Text] [Related]  

  • 19. Natural product drug discovery and development: the United States National Cancer Institute role.
    Cragg GM
    P R Health Sci J; 2002 Jun; 21(2):97-111. PubMed ID: 12166031
    [No Abstract]   [Full Text] [Related]  

  • 20. Contrasting viewpoints on cancer drug development: the Wooldridge and Richardson reports.
    DeVita VT
    Cancer Treat Rep; 1984 Jan; 68(1):339-40. PubMed ID: 6692433
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.